Soybean peptide fractions inhibit human blood, breast and prostate cancer cell proliferation

Area of Science:

• Biochemistry
• Molecular Biology
• Nutritional Science

Background:

• Soybean seed proteins can be processed into peptide fractions.
• These fractions may possess bioactive properties relevant to human health.
• Investigating their anticancer potential is of interest for therapeutic applications.

Purpose of the Study:

• To evaluate the in vitro anticancer bioactivity of soybean peptide fractions.
• To assess the inhibitory effects on human blood, breast, and prostate cancer cell lines.
• To determine the dose-response relationship of effective peptide fractions.

Main Methods:

• Preparation of gastrointestinal-treated peptide fractions (<5, 5-10, and 10-50 kDa) from soybean lines.
• In vitro testing using anti-proliferative cell titer assay against CCRF-CEM, Kasumi-3, MCF-7, and PC-3 cancer cell lines.
• Trypan blue dye exclusion assay to determine the half-maximal inhibitory concentration (IC50).

Main Results:

• Soybean peptide fractions demonstrated significant inhibition of cancer cell proliferation, up to 68.0%.
• The half-maximal inhibitory concentration (IC50) ranged from 608 to 678 µg/mL.
• Different peptide fractions exhibited varying degrees of efficacy against the tested cancer cell lines.

Conclusions:

• Soybean peptide fractions exhibit promising in vitro anticancer activity against multiple human cancer cell lines.
• These gastrointestinal-friendly peptides hold potential as functional food ingredients or nutritional supplements.
• Further research could explore their application in alternative cancer therapy strategies.